SCHEMBL428507

SCHEMBL428507

Cc1cccc(C)c1C1CC(=O)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 3/20 0.43
LDHB P07195 2/20 0.43
ACHE P22303 1/20 0.41
AADAT Q8N5Z0 2/20 0.40
MAPT P10636 2/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAP3K14 Q99558 1/20 0.36
CREBBP Q92793 2/20 0.36
BRD4 O60885 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2A6 P11509 1/20 0.35
TRPA1 O75762 1/20 0.34
TP53 P04637 1/20 0.34
RECQL P46063 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PBRM1 Q86U86 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5335162 0.91 MAPT (0.50) LDHALDHBACHEAADATMAPT
SCHEMBL30851861 0.86 ACHE (0.40) LDHALDHBACHEAADAT
SCHEMBL25376123 0.78 LDHA (0.40) LDHALDHBACHEAADATMAPT
SCHEMBL25373270 0.76 LDHA (0.39) LDHALDHBMAPTGAAALDH1A1
SCHEMBL426358 0.76 HTR2C (0.52) MAPTGAAALDH1A1TP53RECQL
SCHEMBL16959393 0.75 ALDH1A1 (0.46) ACHEALDH1A1MAP3K14CYP1A2CYP2A6
SCHEMBL13454025 0.72 MAPT (0.44) LDHALDHBMAPTGAATP53
SCHEMBL2702396 0.70 CXCR5 (0.42) GAAALDH1A1MAP3K14HSD11B1
SCHEMBL2722636 0.70 CXCR5 (0.42) GAAALDH1A1MAP3K14HSD11B1
SCHEMBL12676482 0.70 TP53 (0.53) ACHEMAPTGAATP53RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2481735-A1 Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials Pfizer Inc. (US) 2012-08-01 EP disclosed
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2012-03-15 US disclosed
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2012-03-15 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
WO-2008139288-A2 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS PFIZER INC. (US) 2008-11-20 WO disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 LDHA 3612/4885LDHB 3314/4885ACHE 1167/4885
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 LDHA 3612/4885LDHB 3314/4885ACHE 1167/4885
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions XDH, CYP2D6, F12 LDHA 3612/4885LDHB 3314/4885ACHE 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.